No Data
No Data
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NeuroBo Pharmaceuticals GAAP EPS of -$1.85
Buy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental Pipeline
NeuroBo Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
NeuroBo Pharmaceuticals Shares Rise After Reporting Q2 Results
NeuroBo Pharmaceuticals Q2 EPS $(1.85) Misses $(1.12) Estimate
No Data
No Data